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Abstract Evidence exists for an immunomodulatory
effect of endocrine therapy in hormone receptor-positive
(HR?ve) breast cancer (BC). Therefore, the aim of this
study was to define the prognostic and predictive value of
tumor immune markers and the tumor immune profile in
HR?ve BC, treated with different endocrine treatment
regimens. 2,596 Dutch TEAM patients were treated with
5 years of adjuvant hormonal treatment, randomly assigned
to different regimens: 5 years of exemestane or sequential
treatment (2.5 years of tamoxifen–2.5 years of exemes-
tane). Immunohistochemistry was performed for HLA
class I, HLA-E, HLA-G, and FoxP3. Tumor immune sub-
types (IS) (low, intermediate & high immune susceptible)
were determined by the effect size of mono-immune
markers on relapse rate. Patients on sequential treatment
with high level of tumor-infiltrating FoxP3? cells had
significant (p = 0.019, HR 0.729, 95 % CI 0.560–0.949)
better OS. Significant interaction for endocrine treatment
and FoxP3? presence was seen (OS p \ 0.001). Tumor IS
were only of prognostic value for the sequentially endo-
crine-treated patients (RFP: p = 0.035, HR intermediate IS
1.420, 95 % CI 0.878–2.297; HR low IS 1.657, 95 % CI
1.131–2.428; BCSS: p = 0.002, HR intermediate IS 2.486,
95 % CI 1.375–4.495; HR low IS 2.422, 95 % CI
1.439–4.076; and OS: p = 0.005, HR intermediate IS
1.509, 95 % CI 0.950–2.395; HR low IS 1.848, 95 % CI
1.277–2.675). Tregs and the tumor IS presented in this
study harbor prognostic value for sequentially endocrine-
treated HR?ve postmenopausal BC patients, but not for
solely exemestane-treated patients. Therefore, these
markers could be used as a clinical risk stratification tool to
guide adjuvant treatment in this BC population.
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Introduction
Breast cancer (BC) is the most commonly diagnosed female
cancer in the developed world and also a leading cause of
cancer death, responsible for 14 % of cancer-related deaths in
women of the West [1]. Nowadays, BC treatment consists of a
combination of locoregional treatment (i.e., surgery and
radiotherapy) and systemic therapy (i.e., chemotherapy and
hormonal therapy), to concur present and less evident metas-
tasis. In the USA, an increased tendency of adjuvant treatment
allocation using genomic expression assays such as Oncotype
DX (genomic health, redwood city, CA, USA) and Mamma-
print (Agendia, Amsterdam, the Netherlands), providing
additional information about the risk of relapse and benefit of
adjuvant chemotherapy, is seen [2–4]. However, in the Neth-
erlands, decisions regarding the use of adjuvant systemic
therapy in primary BC patients are still mainly based on clas-
sical prognostic factors, like lymph node status, tumor size, and
grade, hormone receptor (HR) and human epidermal growth
factor receptor 2 (HER2) expression [5]. However, currently
these do not provide optimal risk stratification, resulting in
over- and under treatment of certain patients. There is evidence
that a host’s cellular immune response plays a pivotal role in
controlling tumor progression through a number of immuno-
logical mechanisms, involving classical human leukocyte
antigen (HLA) class I and non-classical HLA-E and HLA-G
expression by the tumor, and presence of tumor-infiltrating
cytotoxic T cells (CTL), Natural Killer (NK) cells, and regu-
latory T cells (Tregs) [6–11], suggesting that complex inter-
actions take place between breast tumor cells and immune cells
[12]. Valuable prognostic interactions reported are those
between classical HLA class I and Tregs, where loss of HLA
class I in combination with the presence of Treg in the tumor
microenvironment resulted in a worse patient’s outcome, and
also the interaction between classical HLA class I, HLA-E, and
HLA-G tumor expression, where HLA-E and HLA-G
expression resulted in worse patient outcome in the co-
occurrence of loss of classical HLA class I on the tumor surface
[8, 9, 12]. Together, this emphasizes the importance of research
on combinations of markers of immune surveillance together
with markers of tumor immune escape.
Our group previously constructed breast tumor immune
subtypes (IS) by combining markers of immune surveil-
lance together with markers of tumor immune escape,
based on a biological rationale [13]. Data revealed strong
associations with patient outcome whereby tumors defined
as highly susceptible to immune attack showed favorable
clinical outcome compared to patients with tumors har-
boring a low immune susceptibility profile, independent of
known clinicopathological parameters [13]. In the current
study, we used another approach to define tumor IS. Tumor
immune mono-markers in Dutch postmenopausal hor-
mone-sensitive BC patients from the Tamoxifen and Exe-
mestane Adjuvant Multicenter (TEAM) trial were
correlated to clinical outcome. Subsequently, we designed
tumor immune subtypes based on statistical effect sizes of
the immune mono-markers on relapse rate.
It has already been shown that tumor-infiltrating lym-
phocytes (TILs) act as an independent predictor of
response to chemotherapy treatment [14–16]. Elaborating
on this result, evidence also exists for an immunomodu-
latory effect of tamoxifen; it is thought that tamoxifen
induces a shift from cellular (T-helper 1) to humoral (T-
helper 2) immunity [17]. Given the fact that T-helper 1
immunity is essential for anti-tumor immune response, a
tamoxifen-induced shift away from cellular immunity may
represent a significant step in tumor development. This
would hamper the cytotoxic effect of tamoxifen and pos-
sibly explain the differential effect of aromatase inhibitors
versus tamoxifen on clinical outcome [17–19].
The aim of our current study was therefore to investigate
the difference in prognostic value of tumor IS in relation




Eligibility criteria for the TEAM study have been previously
described [20]. In brief, patients were postmenopausal and had
HR?ve early BC diagnosed between 2001 and 2006. Patients
with bilateral tumors or prior history of cancer were excluded.
Patients were randomly assigned in a 1:1 ratio to either exe-
mestane, 25 mg daily for 5 years, or sequential therapy con-
sisting of tamoxifen 20 mg daily for 2.5 years followed by
exemestane 25 mg daily for another 2.5 years [20].
Medical-ethical approval was obtained and the study was
conducted in accordance with the Declaration of Helsinki.
All TEAM patients gave informed consent prior to enroll-
ment in the study. Surgically resected, formalin-fixed, par-
affin-embedded (FFPE) tumor samples of the Dutch TEAM
patients (n = 2596) were used. All samples were handled in
a coded fashion, according to national ethical guidelines
(‘‘Code for Proper Secondary Use of Human Tissue’’, Dutch
Federation of Medical Scientific Societies).
Data were centrally collected at the Datacenter of the
Department of Surgery of the Leiden University Medical
Center. For all patients, the following data were known:
age at diagnosis, histological tumor grade, HR status,
tumor size and nodal stage, type(s) of local and systemic
treatment, date and type of disease recurrence, and death
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and follow-up data. Reporting of the biomarkers was done
according to the REMARK criteria [21].
Immunohistochemistry
Immunohistochemical staining was performed on 4 lm FFPE
Tissue Micro Array sections consisting of breast cancer tissue
of the Dutch TEAM patients (three 0.6 mm2 tumor tissue
punches per patient) [22]. The tissue sections were stained
according to the previously described protocol [9]. Sections
were incubated at room temperature over night with mouse
monoclonal antibodies HCA2 and HC10 (anti-HLA-A and
anti-HLAB/C, respectively) [9, 23] for the detection of clas-
sical HLA class I on the tumor cell surface. Non-classical
HLA class I staining was performed using mouse monoclonal
antibodies against HLA-E (MEM-E/02 Clone (sc-51621,
Santa Cruz biotechnology, Dallas, Texas) and HLA-G (4H84
Clone (sc-21799, Santa Cruz Biotechnology, Dallas, Texas)
[8]. Mouse monoclonal antibodies against FoxP3 (clone
236A/E7 (ab20034, Abcam, Cambridge, United Kingdom))
were used to identify Tregs [9]. All slides were stained
simultaneously to avoid inter-assay variation.
Evaluation of immunostaining
Microscopic quantification of positive tumor cells for
HCA2, HC10, HLA-E, and HLA-G was performed in a
blinded manner by two independent observers (C.C.E., A.S.
and A.v.V). The scores of the three tissue cores were aver-
aged. For HCA2 and HC10, the percentage of tumor cells
with membranous staining was assessed. Classical HLA
class I expression status was determined according to the
standard set by the International HLA and Immunogenetics
Workshop [24]. According to this standard, HCA2 and
HC10 staining were scored in two categories: score 1
(0–5 % of tumor cells positively stained) or score 2
(5–100 % of tumor cells positively stained). Three groups
were defined for classical HLA class I expression: HLA
class I loss (both HCA2 and HC10 scored 0–5 %); HLA
class I down-regulation (either HCA2 or HC10 scored
0–5 %); and HLA class I expression (both HCA2 and HC10
scored 5–100 %) [9]. For non-classical HLA class I markers,
both HLA-E and HLA-G were scored based on the per-
centage of tumor cells with membranous staining and re-
categorized in a binary manner. Any specific staining of
tumor cells was considered positive and no staining was
considered negative for HLA-G. HLA-E expression was
divided into quartiles, of which the first quartile was cate-
gorized as low HLA-E expression and subsequent quartiles
([first quartile) as high. FoxP3? nuclear presence per mm2
in tumor epithelium and surrounding stroma tissue was
identified with the use of a Panoramic Midi scanner
(3DHistech, Hungary) by means of an automated positive
cell count analysis using AxioVision 4.6 (Carl Zeiss Vision,
Jena, Germany). FoxP3? presence was scored by two cat-
egories: low (B49 positive cells) and high ([49 positive
cells) Treg infiltration per mm2, based on the median value.
Statistical analysis
Statistical analyses were performed using statistical package
SPSS (version 20.0 for Windows, IBM SPSS statistics).
Patients whose tumor material was lost during staining pro-
cedure were excluded from analyses. Cohen’s kappa coeffi-
cient was used to assess inter-observer agreement in
quantification of HCA2, HC10, HLA-E, and HLA-G. As BC
relapse strongly influences survival rates of BC patients, we
designed tumor IS, by combining classical HLA-I, HLA-E,
and HLA-G, and FoxP3, based on the regression coefficient of
these mono-markers in the Cox-regression using relapse-free
period (RFP) as clinical endpoint for all tumor samples. The
regression coefficient was used for IS configuration because
different modes of immunohistochemical scoring were used
for the different markers, making a simple additive approach
for the individual scores to construct the IS undesirable. Fur-
thermore, usage of the regression coefficient results in
accounting for an accurate degree of impact of an immuno-
histochemical score on clinical outcome. The regression
coefficient value, indicating either negative or positive clinical
effect, served as a penalty or bonus (in case of a negative or
positive slope, respectively). All regression coefficients (for
HLA-I, HLA-E, HLA-G and FoxP3 ?) were added up to
construct the final score per patient. Ultimately, three groups:
low, intermediate, and high immune-susceptible tumor types
were constructed based on tertile (B33, [33, B 67
and [67 %) cut-off points of the final score.
The v2 test was used to evaluate associations between
the tumor immune mono-markers, and also between clin-
icopathological parameters and tumor immune mono-
markers and tumor IS. The clinical endpoints were RFP,
defined as time from date of randomization in the TEAM-
trial until any recurrence (locoregional recurrence and/or a
distant recurrence, whichever came first), breast cancer-
specific survival (BCSS), defined as time from date of
randomization until death due to BC, and overall survival
(OS), defined as time from randomization until death by
any reason. The Kaplan–Meier method was used for sur-
vival plotting and log-rank test for RFP, BCSS, and OS
curve comparison. Cox proportional hazard analysis was
used for univariate analysis and was additionally adjusted
for clinically relevant confounders (age, pathological tumor
and nodal stage, tumor grade, histology, and treatment). All
analyses were stratified for hormonal regimen (exemestane
or sequential regimen). Interaction between endocrine
treatment and tumor IS was tested in a multivariable
model.
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Results
Patient and tumor characteristics
The Dutch TEAM cohort consists of 2596 postmenopausal
non-metastasized BC patients with a median age of
65 years (range 38–91 years). Median follow-up of
patients was 5.9 years. Clinicopathological and treatment
characteristics in relation with tumor IS are shown in
Table 1. Only for radiotherapy a significant difference
(Chi-square test, p = 0.045) was seen between tumor IS,
showing less radiotherapy treatment for intermediate tumor
IS compared to low and high tumor IS. Substantial agree-
ment (J C 0.6) was observed for quantification of all
immunohistochemical stainings.
Classical HLA-I expression and association
with prognosis
Microscopic quantification for classical HLA-I was suc-
cessful in 73 % (1891/2596) of tumors (79 % (2042/2596)
for HCA2 and 80 % (2083/2596) for HC-10). Classical
HLA-I loss was found in 16 % (298/1891), down-regula-
tion in 27 % (513/1891), and expression in 57 % (1080/
1891)(Supplementary Table 1A). In the analyses stratified
for endocrine treatment, no significant difference in out-
come was seen for HLA-I expression in RFP, BCSS, or OS
(Supplementary Table 2A).
HLA-E and HLA-G expression and association
with prognosis
Successful staining for HLA-E was obtained in 74 % of
tumors, and in 79 % for HLA-G. Low HLA-E was found in
26 % (495/1914) and high expression in 74 % (1419/1914)
of the patients, whereas absence of HLA-G was found in
76 % (1558/2042) and expression in 24 % (484/2042) of
the patients (Supplementary Table 1B). Neither of the two
immune markers showed significant association with clin-
ical outcome when stratified for endocrine treatment
received (Supplementary Table 2B and 2C).
Presence of FoxP3? cells and association
with prognosis
Automated positive cell count was successful in 93 %
(2426/2596) of tumors for FoxP3? cells. Low (Bmedian
value of 49 cells) number of positive cells was seen in
51 % (1241/2426) and high number ([ median of 49
positive cells) in 49 % (1185/2426) of the patients (Sup-
plementary Table 1A). Patients on sequential hormonal
therapy showed a significant (univariate: p = 0.026, mul-
tivariate: p = 0.019, HR: 0.729, 95 % CI 0.560–0.949)
preferential outcome for high FoxP3? presence in OS, but
not for RFP or BCSS. No association with clinical outcome
was seen for patients in the exemestane-only treated arm
(univariate OS: p = 0.138, HR 0.821, 95 % CI:
0.633–1.065) (Supplementary Table 2D). The multivari-
able interaction model showed a significant predictive
effect for endocrine treatment and FoxP3? presence
(p value OS \ 0.001) in OS.
Tumor immune subtypes and association
with prognosis
In view of recent evidence stating that the interaction
between tumor cells and cells of the immune system is
multifaceted and complex [13], we hypothesized that
combined analyses of immune markers may better reflect a
patients’ outcome by taking into account the interaction
between tumor cells and cells of the immune system. First,
when the four mono-markers were tested in relation to one
another in the Chi-square test, results showed a significant
association between all four mono-markers (Chi-square
test, p values: all \0.001, data not shown). No difference in
distribution was observed for the defined risk groups in the
two hormonal treatment arms (p = 0.726). Based on the
tumor IS model described in the Materials and methods
section, which is based on the regression coefficient of the
mono-markers in the RFP, high tumor immune suscepti-
bility was characterized by either classical HLA-I expres-
sion with HLA-EG presence or absence (HLA-EG absence:
both or either HLA-E or HLA-G not expressed; HLA-EG
positive: both HLA-E and HLA-G positive) on the tumor
surface, known for its activation of Natural Killer (NK)
cells [8], or classical HLA-I loss or down-regulation
combined with mostly HLA-EG absence. Treg presence
was equally distributed in the high IS tumor subtypes.
Great variability in Treg presence was also seen in the low
and intermediate tumor IS (Supplementary Table 3). The
tumor IS showed significant preference for the high
immune-susceptible tumor types for clinical outcome
(RFP: p = 0.002, HR intermediate (vs. high) tumor IS
1.539, 95 %CI 1.088–2.178; HR low (vs. high) tumor IS
1.634, 95 % CI 1.235–2.163; BCSS: p \ 0.001, HR
intermediate (vs. high) tumor IS: 2.119, 95 % CI
1.368–3.283; HR low (vs. high) tumor IS 2.103, 95 % CI
1.456–3.038); OS: p = 0.002, HR intermediate (vs. high)
tumor IS 1.471, 95 % CI 1.065–2.032; HR low (vs. high)
tumor IS 1.602, 95 % CI 1.235–2.077) (Fig. 1).
Immune subtypes and adjuvant endocrine treatment
Significant differences were seen for RFP, BCSS, and OS
in the sequentially endocrine-treated patient group when
stratified for adjuvant hormonal treatment. Again, all
590 Breast Cancer Res Treat (2015) 149:587–596
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outcomes are in favor of high tumor immune susceptibility
(RFP: sequential treatment: p = 0.035, HR intermediate IS
(versus high) 1.420, 95 % CI 0.878–2.297; HR low IS
(versus high): 1.657, 95 % CI 1.131–2.428;
BCSS:sequential treatment: p = 0.002, HR intermediate IS
(vs. high) 2.486, 95 % CI 1.375–4.495; HR low IS (vs.
Table 1 Patient and tumor characteristics
High immune subtype Intermediate immune subtype Low immune subtype p value
N = 501 % N = 318 % N = 817 %
Age
\ 65 259 51.7 164 51.6 425 52.0 0.988
C 65 242 48.3 154 48.4 392 48.0
Missing 0 0 0
pT stage
T1 227 45.4 126 39.6 385 47.2 0.218
T2 244 48.8 169 53.1 387 47.4
T3-4 29 5.8 23 7.2 44 5.4
Missing 1 0 1
pN stage
N0 143 28.5 107 33.6 277 33.9 0.373
N1 319 63.7 192 60.4 490 60.0
N2-3 39 7.8 19 6.0 49 6.1
Missing 0 0 1
Grade
I 66 13.9 55 18.5 98 12.6 0.100
II 222 46.8 134 45.1 348 44.8
III 186 39.3 108 36.4 330 42.6
Missing 27 21 41
Histology
Ductal 391 78.5 249 78.6 664 81.8 0.495
Lobular 65 13.1 40 12.6 79 9.7
Mixed 18 3.6 14 4.4 37 4.6
Other 24 4.8 14 4.4 32 3.9
Missing 3 1 5
Operation
Mastectomy 263 52.5 183 57.5 434 53.1 0.318
BCS 238 47.5 135 42.5 383 46.9
Missing 0 0 0
Radiotherapy
Yes 318 63.5 174 54.9 500 61.2 0.045
No 183 143 317
Missing 0 1 0
Chemotherapy
Yes 129 25.7 102 32.2 247 30.2 0.097
No 372 74.3 215 67.8 570 69.8
Missing 0 1 0
Endocrine therapy
EXE 257 51.3 154 48.4 410 50.2 0.726
TAM ? EXE 244 48.7 164 51.6 407 49.8
0 0 0
EXE exemestane, TAM tamoxifen
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high) 2.422, 95 % CI 1.439–4.076; and OS:sequential
treatment: p = 0.005, HR intermediate IS (vs. high) 1.509,
95 % CI 0.950–2.395; HR low IS (versus high) 1.848,
95 % CI 1.277–2.675) (Table 2; Fig. 2). No prognostic
value was seen for the solely exemestane-treated patients.
A statistical trend was seen for the interaction between
endocrine treatment and tumor IS in the multivariable
interaction model (p value RFP: 0.15, BCSS: 0. 19 and OS:
0.17).
Discussion
Evidence is building for an increasingly important role of
tumor–immune interaction with regard to clinical outcome
of cancer patients [25]. To our knowledge, this is the first
study reporting on the effect of endocrine treatment on the
prognostic value of Treg cells and tumor IS in a HR?ve
BC cohort.
Our data suggest a positive effect of Treg presence on
overall survival outcome in the sequentially endocrine-
treated patient group, which is further supported by a
highly significant interaction term for endocrine treatment
and Treg presence. This could possibly be explained by
recent data indicating that Tregs harbor a dual role in
cancer, suppressing anti-tumor immune response (induc-
ible Treg) and suppressing inflammation which is known to
promote carcinogenesis (natural Treg) [26, 27]. These
same studies suggest that the clinical and prognostic sig-
nificance of Tregs in cancer depends on its environmental
factors. Our investigated patient population harbors a
number of pro-inflammatory risk factors, namely a post-
menopausal status which is known to be associated with
systemic inflammation, and HR?ve breast tumors [28].
Assuming that HR?ve tumors attract higher estrogen lev-
els in and around the tumor due to an increased tendency of
estrogen binding, we hypothesize that this estrogen-rich
environment leads to higher Adenosine Deaminase Gene
expression, which in turn is responsible for the degradation
of Adenosine (ADO), a potent anti-inflammatory agent [29,
30]. This presumed high inflammatory state in our patient
population would assume a preference for natural Tregs,
explaining the positive effect of high FoxP3? presence in
the tumors and the loss of prognostic significance in solely
exemestane-treated patients, as aromatase inhibition leads
to lower estrogen levels, which will diminish ADO
degradation.
For BC patients treated with sequential endocrine ther-
apy, the tumor IS bare a strong independent significant
prognostic value for BC-specific survival and also,
although to a lesser degree, for relapse rate and overall
survival, while this association was not seen for patients
treated solely with aromatase inhibition for five consecu-
tive years. These data might imply that the immune profile
of the breast tumor in sequentially endocrine-treated breast
cancer patients could predict BC death and overall death in
HR?ve breast disease, and thus additional adjuvant ther-
apy, such as chemotherapy and radiotherapy, could be
optimally allocated based on this prognostic indicator.
Since no prognostic effect was noted for the tumor IS in the
solely exemestane-treated patient population, the question
remains whether there would be any benefit of additional
adjuvant treatment for these patients, suggesting that cur-
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Fig. 1 Tumor immune subtypes [high, intermediate, and low tumor
immune subtypes (IS)] in relation with clinical outcome parameters:
relapse-free period (RFP), breast cancer-specific survival (BCSS), and
overall survival (OS), shown with corresponding adjusted (age, pT
stage, pN stage, tumor grade, histology, surgery type, chemotherapy,
radiotherapy, and endocrine therapy) p values
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outcome with five consecutive years of exemestane treat-
ment, even for the low tumor immune-susceptible HR?ve
patient population. However, the multivariable interaction
term for endocrine treatment and breast tumor immune
subtypes hinted to a possible statistical trend for clinical
outcome. The lack of significance in this test could be
explained by the limited power of the statistical interaction
test and also due to the low number of clinical events in our
cohort.
In this study, it was hypothesized that high immune-
susceptible tumor types, due to a tamoxifen-induced shift
from Th1 to Th2 immunity, would have the highest like-
lihood of showing regression of clinical outcome to mean
relapse and survival rates of the overall cohort. Based on
the data presented in this manuscript, the difference in
prognostic value of tumor immune subtyping between the
two endocrine treatment arms cannot be explained by the
previously described tamoxifen-driven shift from Th1 to
Th2 immunity [17]. In that case, it would be expected that
the difference in prognosis between the high immune-
susceptible tumor subtype, which is expected to be strongly
dependent on cellular Th1 immunity, and the low and
intermediate subtypes would be minimized. Reason for this
could be that highly immunogenic tumors have the ability
to circumvent the inferior immune response caused by the
tamoxifen-induced Th1-to-Th2 shift, by means of other
immune interactions not requiring Th1 activation. A pos-
sible explanation for the loss of prognostic value of the
tumor IS in the exemestane-treated patient arm of this
cohort could also be Treg dependent. Findings supporting
exemestane-induced loss of Treg are published by Chan
et al., showing a significant increase in the CD8?/Treg
ratio in ER?ve patients, responding well to aromatase-
inhibiting therapy, herewith reflecting the dynamic process
in which the host’s immune response to tumor antigens
changed in consequence of estrogen depletion caused by
the aromatase inhibitor [31]. Similarly, Generali et al.
observed that FoxP3? cell counts decreased significantly
after letrozole treatment [32]. Therefore, one could
hypothesize that in this specific HR?ve, postmenopausal
BC cohort, exemestane-induced loss of highly prognostic
Treg cells could lead to equalization of the clinical out-
comes of the three tumor IS in the solely exemestane-
treated adjuvant treatment arm. If this would be true, one
could speculate on the great importance of Treg for inhi-
bition of tumor development in a postmenopausal, HR?ve
tumor environment, thereby proposing that under these
conditions, HLA-I, HLA-E, and HLA-G seem to merely
have a supportive role in relation to Treg cells.
This is the first study that assessed the relation between
adjuvant endocrine therapy and the prognostic value of
tumor immune markers and tumor IS of postmenopausal
Table 2 Cox univariate and multivariate analysis for overall survival (OS) and relapse-free survival (RFS) stratified for different endocrine
therapy regimens for tumor immune subtypes classified into 3 groups
Outcome Hormone therapy Immune subtype N Univariate Multivariatea
HR 95 %CI p HR 95 %CI p Interaction p
RFP EXE High 257 1.00 0.113 – – – 0.15
Intermediate 154 1.556 0.958–2.526
Low 410 1.464 0.988–2.171
RFP TAM ? EXE High 244 1.00 0.086 1.00 0.035
Intermediate 164 1.343 0.850–2.122 1.420 0.878–2.297
Low 407 1.520 1.049–2.203 1.657 1.131–2.428
BCSS EXE High 257 1.00 0.261 – – – 0.19
Intermediate 154 1.482 0.812–-2.708
Low 410 1.465 0.907–2.367
BCSS TAM ? EXE High 244 1.00 0.002 1.00 0.0
Intermediate 164 2.486 1.375–4.495 2.848 1.509–5.375 01
Low 407 2.422 1.439–4.076 2.869 1.651–4.984
OS EXE High 257 1.00 0.204 – – – 0.17
Intermediate 154 1.428 0.925–2.205
Low 410 1.311 0.924–1.858
OS TAM ? EXE High 244 1.00 0.024 1.00 0.005
Intermediate 164 1.531 0.993–2.362 1.509 0.950–2.395
Low 407 1.636 1.144–2.341 1.848 1.277–2.675
TAM tamoxifen, EXE exemestane
a Adjusted for age, pT stage, pN stage, tumor grade, histology, surgery type, chemotherapy, and radiotherapy
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HR?ve, early BC patients. Of course, the external validity
of our results should be investigated in other large studies
with tumor material available of HR?ve BC patients
treated with different hormonal regimens, such as, for
example the ATAC, BIG, or IES study [18, 33, 34]. The
major strength of this study is the use of data from the
TEAM-trial, as this provides well-registered data in a large
number of patients. This study, however, also has its lim-
itations. First, one could stress the shortcomings of FoxP3
staining, without co-staining of CD25 and CD4, for the
detection of Tregs. Herewith, the margin of error for mis-
takenly scoring FoxP3? breast tumor cells is increased
[35]. However, based on careful review of the histology of
the breast cancer tissue and given the fact that the majority
of FoxP3? cells were seen in the stromal region of the
tumor tissue, we can state with reasonable certainty that the
majority of positive cells were true Treg cells. Second,
there were no standard tumor IS categories available from
previous literature. Therefore, we categorized patients by
tumor IS based on the regression coefficient of the mono-
markers in the Cox-regression using RFP. One could crit-
icize that this is an over-fitted model for RFP, but our
results also showed significant association with the other
clinical outcome parameters BCSS and OS. Furthermore,
our results did not show a difference in the distribution of
the tumor IS for the two hormonal treatment arms; never-
theless, results showed a clear significant difference in the
prognostic value of the IS based on the hormonal treatment
received. Third, patients on sequential hormonal therapy
received exemestane after the first 2.5 years of tamoxifen
Fig. 2 Tumor immune
subtypes [high, intermediate,
and low tumor immune




(BCSS), and overall survival
(OS), shown with corresponding
p values (as seen in Table 3)
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treatment. It would be desirable to compare two endocrine
treatment regimens, consisting of solely exemestane and
solely tamoxifen given for five consecutive years, elimi-
nating the potential immune-modulating effects of endo-
crine drugs with a different mode of action. Lastly, the
immune contributions on clinical outcome described in this
manuscript are all based on surgically derived tumor
material, assuming that metastasizing cells harbor the same
immunogenic characteristics. It should not be ignored that
this approach disregards the possible interplay of systemic
immune cells which undoubtedly also play a major role in
anti-tumor immunity.
In conclusion, when taking into account the difference in
associations of the tumor immune markers and tumor IS per
endocrine treatment arm, these data partially support the
hypothesis of previous manuscripts stating that endocrine
treatment harbors an immune-modulating effect [17, 31].
Nonetheless, this study merely showed a statistical trend for
interaction between tumor IS and type of endocrine treatment,
and a strong interaction for FoxP3? cells present in the tumor
and endocrine treatment, implying that based on the data
presented in this manuscript, the difference in prognostic
value of tumor immune subtyping between the two endocrine
treatment arms cannot be explained by the previously
described tamoxifen-driven shift from Th1 to Th2 immunity
[17]. In that case, it would be expected that the difference in
prognosis between the high immune-susceptible tumor sub-
type, which is expected to be strongly dependent on cellular
Th1 immunity, and the low and intermediate subtypes would
be minimized. Reason for this could be that highly immuno-
genic tumors have the ability to circumvent the inferior
immune response caused by the tamoxifen-induced Th1-to-
Th2 shift, by means of other immune interactions not requir-
ing Th1 activation. A possible explanation for the loss of
prognostic value of the tumor IS in the exemestane-treated
patient arm of this cohort could also be Treg dependent.
Findings supporting exemestane-induced loss of Treg are
published by Chan et al., showing a significant increase in the
CD8 ?/Treg ratio in ER ? ve patients, responding well to
aromatase-inhibiting therapy, herewith reflecting the dynamic
process in which the host’s immune response to tumor anti-
gens changed in consequence of estrogen depletion caused by
the aromatase inhibitor [31]. Similarly, Generali et al.
observed that FoxP3? cell counts decreased significantly
after letrozole treatment [32]. Therefore, one could hypothe-
size that in this specific HR?ve, postmenopausal BC cohort,
exemestane-induced loss of highly prognostic Treg cells
could lead to equalization of the clinical outcomes of the three
tumor IS in the solely exemestane-treated adjuvant treatment
arm. If this would be true, one could speculate on the great
importance of Treg for inhibition of tumor development in a
postmenopausal, HR ? ve tumor environment, thereby pro-
posing that, despite the call for strong immune cell interplay
recognition in tumor development, under these specific con-
ditions, HLA-I, HLA-E, and HLA-G seem to merely have a
supportive role in relation to Treg cells.
To the best of our knowledge, this is the first study
showing different associations in the prognostic value of
tumor-infiltrating Tregs and tumor IS with adjuvant endo-
crine treatment, and thus could be used as a clinical risk
stratification tool in sequentially endocrine-treated HR?ve,
postmenopausal BC patients. Therewithal, the results of
this study add to previous studies on tumor–immune
interactions in BC [6, 13, 17, 36, 37]. More research is
needed to further elucidate this clinically relevant matter.
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